North America Competent Cells Market Size, Share & Trends Analysis Report By Type, By Application (Cloning, Protein Expression, Mutagenesis, and Others), By End-Use, By Country and Growth Forecast, 2024 - 2031

The North America Competent Cells Market is projected to witness market growth of 7.3% CAGR during the forecast period (2024-2031).

The US market dominated the North America Competent Cells Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $898.8 million by 2031. The Canada market is experiencing a CAGR of 9.4% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 9.4% during (2024 - 2031).



These cells, particularly Escherichia coli (E. coli) and other bacterial strains have a wide range of applications across various fields within biotechnology, pharmaceuticals, agriculture, and research. These cells are essential for molecular cloning techniques, where they are used to introduce foreign DNA into bacterial cells. This process involves transforming these cells with recombinant DNA molecules, typically carried on plasmids or other vectors. Cloning allows researchers to replicate and study specific DNA sequences, gene functions, and regulatory elements.

These cells serve as hosts for gene expression studies, enabling the production of proteins encoded by cloned genes. Researchers can induce the expression of recombinant proteins in these cells to study protein structure, function, and interactions. This application is crucial for pharmaceutical research, engineering, and therapeutic protein production. These cells are crucial in constructing and screening genomics, cDNA, and protein libraries. These libraries contain cloned DNA fragments or expressed genes, which serve as valuable resources for identifying novel genes, biomarkers, drug targets, and therapeutic candidates.

As pharmaceutical companies in Canada intensify their research efforts, there will be a higher demand for these cells used in genetic engineering and drug development processes. According to Statistics Canada, in 2020, the R&D pharmaceutical sector contributed $15.9 billion to the Canadian economy in GVA, an increase of 5.8% from the $15.0 billion generated in 2019. Just under half of this ($7.9 billion) was attributable to the direct impacts of the sector, which rose 4.5% from the $7.6 billion generated in 2019. Furthermore, The Mexican government, through agencies like CONACYT (Consejo Nacional de Ciencia y Tecnología), provides research grants and funding opportunities specifically targeted at biotechnology and life sciences. These funds support research projects that require these cells for applications such as genetic engineering, biopharmaceutical development, and agricultural biotechnology. Therefore, rising R&D in pharmaceutical industry and rising government initiative are propelling the growth of the market.

List of Key Companies Profiled

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Promega Corporation
• New England Biolabs, Inc.
• Qiagen N.V
• Hoffmann-La Roche Ltd.
• Takara Bio Inc. (Takara Holdings Inc.)
• Lonza Group Ltd. (Capsugel)

Market Report Segmentation

By Type

• Chemically Competent Cells
• Electrocompetent Cells
• Ultracompetent Cells

By Application

• Cloning
• Protein Expression
• Mutagenesis
• Others

By End-Use

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America